Melanoma Clinical Trial
Official title:
18F‐Labeled Picolinamide PET-CT in the Management of Patients With Melanoma: The Radiation Dosimetry and Diagnostic Applications in Melanoma Patients
The purpose of this study is to assess the dosimetric properties of the positron emission tomography (PET) imaging probe 18F labeled Picolinamide (18F-P3BZA) and preliminarily evaluate its diagnosis value in melanoma patients.
50 patients with pathology diagnosed melanoma will be enrolled for the clinical study. If
agree to take part in this study, the patient will be performed with 18F-P3BZA PET/CT scan
and 18F-FDG PET/CT scan in the other day before and after surgery. Next, all of the resected
tissues from the patients will be checked with pathology.
6 of 50 patients are performed for whole-body PET scans at 0, 15, 30, 45, 60, and 120
minutes and a CT scan at 60 minutes after tracer injection (mean dose, 5.0 ± 0.5 mCi in 2.0
± 0.5ml) will be performed. During the imaging period, 1 mL blood samples will be obtained
for time-activity curve calculations at 1, 5, 10, 30,60, 90, 120, and 180 minutes after
injection. The estimated radiation doses will be calculated by using OLINDA/EXM software.
The images produced by these scans will be compared to see the diagnosis value of 18F-P3BZA.
Screening Tests:
Women who decide to take part in this study will be asked if they think they might be
pregnant at the start of the study. All of them must have a negative blood pregnancy test
(Human chorionic gonadotropin, HCG).
PET-CT Scan Procedure:
Before the PET-CT scan is performed, patient will be asked to remove any metallic objects
when she/he arrive at the PET-CT Center. After a property rest, he/she will be injected with
about 5mCi 18F-P3BZA. The first scan will take at 60 minutes after injection and a delay
scan will take at 120 minutes after injection. Each PET/CT scan will take about 20 minutes.
After 18F-P3BZA scan, the patient will be asked to avoid stressful exercise. Starting about
12 hours before 18F-FDG scan, he/she will be asked to limit the amount of carbohydrates
until the scans are done.
Follow-Up Visits:
Patients' primary care physician will follow-up them for next 24 hours. After then, they may
order additional imaging or surgical results after this study for follow-up purposes. The
study doctor will review these results to compare them with the PET-CT images. The study
doctors will also review the results of any biopsies you may have had as a result of PET-CT
findings.
This is an investigational study. PET-CT and CT scans are FDA approved and commercially
available.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
| Completed |
NCT03979872 -
Risk Information and Skin-cancer Education for Undergraduate Prevention
|
N/A | |
| Recruiting |
NCT04986748 -
Using QPOP to Predict Treatment for Sarcomas and Melanomas
|
||
| Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
| Recruiting |
NCT05707286 -
Pilot Study to Determine Pro-Inflammatory Cytokine Kinetics During Immune Checkpoint Inhibitor Therapy
|
||
| Active, not recruiting |
NCT05470283 -
Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic Melanoma
|
Phase 1 | |
| Recruiting |
NCT05077137 -
A Feasibility Study Utilizing Immune Recall to Increase Response to Checkpoint Therapy
|
Phase 1 | |
| Active, not recruiting |
NCT02721459 -
XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma
|
Phase 1 | |
| Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
| Recruiting |
NCT05839912 -
Excision of Lymph Node Trial (EXCILYNT) (Mel69)
|
N/A | |
| Recruiting |
NCT04971499 -
A Study of Dapansutrile Plus Pembrolizumab in Patients With PD-1 Refractory Advanced Melanoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05263453 -
HL-085+Vemurafenib to Treat Advanced Melanoma Patients With BRAF V600E/K Mutation
|
Phase 2 | |
| Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT06413680 -
A First-In Human (FIH) Trial to Find Out if REGN10597 is Safe and How Well it Works for Adult Participants With Advanced Solid Organ Malignancies
|
Phase 1/Phase 2 | |
| Completed |
NCT03348891 -
TNF in Melanoma Patients Treated With Immunotherapy
|
N/A | |
| Terminated |
NCT03399448 -
NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells)
|
Phase 1 | |
| Completed |
NCT03171064 -
Exercise as a Supportive Measure for Patients Undergoing Checkpoint-inhibitor Treatment
|
Phase 2 | |
| Not yet recruiting |
NCT05539118 -
Interferon-α1b Combined With Toripalimab and Anlotinib Hydrochloride in Advanced Unresectable Melanoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05171374 -
pRospective Evaluation of Clinical Outcomes in Patients With metAsTatIс melanOma Treated With dabrafeNib and trAmetinib in reaL practicE
|
||
| Withdrawn |
NCT02854488 -
Yervoy Pregnancy Surveillance Study
|